The most effective means of reducing the risk of complications associated with type 2 diabetes is to ensure that each patient achieves and maintains their individualised glycaemic target. New guidance from the National Institute for Health and Clinical Excellence (NICE) provides
recommendations on using liraglutide (Victoza), a new option for patients who do not achieve target HbA1c using currently available therapies.
